Aequus Announces Completion of Dosing in Phase 1 Clinical Trial of Aripiprazole Transdermal Patch

VANCOUVER, BRITISH COLUMBIA--(Dec. 14, 2015) - Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced completion of dosing in the first stage of its Phase I clinical trial for the once-weekly transdermal aripiprazole patch, AQS1301.

This study is the first in a two-stage Phase I proof-of-concept program designed to assess the rate of absorption and to evaluate the profile of drug delivery over a 7-day period with Aequus' transdermal formulation in twelve healthy volunteers. Previous in vitro and animal studies indicated that aripiprazole, in a proprietary formulation, could adequately be absorbed through the skin. The current clinical study is the first time a topical or transdermal formulation has been applied to humans.

The full analysis and top-line results are expected to be announced early in 2016.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS) (AQSZF) is a Vancouver-based, specialty pharmaceutical company primarily focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate product development and maximize the reach of its product candidates worldwide. Through the recent acquisition of TeOra Health, Aequus now has a Canadian commercial platform to build on for the launch of products that are either created internally or brought in through an acquisition or license, remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.